Michael Stefanidakis, et al. Development of a Subretinally Delivered CEP290-Specific CRISPR Medicine for the Treatment of Leber Congenital Amaurosis 10 (LCA10), October 19, 2017.

Jan

13

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan

6

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec

12

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years